CD39
ENTPD1proteinCD39 ectonucleotidase hydrolyzes ATP and ADP to adenosine monophosphate, attenuating platelet activation and arterial thrombosis.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleATP/ADP hydrolysis, anti-thrombotic; blocks platelet activation.
Also acts inEndothelial activation/erosion
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000138185
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I69
C — confounder / Type-II77
A — assay feasibility68
E — evidence strength30
T1DI (composite)10
Specificity differential (R−C)-7.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(13)
- CD39 polymorphism enables lung thrombosis in sickle cell disease.Nature communications · 2026 · PMID 41530145 · doi
- Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.Frontiers in immunology · 2022 · PMID 35173744 · doi
- Thrombo-Inflammation: A Focus on NTPDase1/CD39.Cells · 2021 · PMID 34571872 · doi
- Ectonucleotidase CD39-driven control of postinfarction myocardial repair and rupture.JCI insight · 2017 · PMID 28097233 · doi
- ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.Journal of the American Heart Association · 2017 · PMID 28751543 · doi
- Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2016 · PMID 27417582 · doi
- Extracellular ATP metabolism on vascular endothelial cells: A pathway with pro-thrombotic and anti-thrombotic molecules.Vascular pharmacology · 2015 · PMID 25989108 · doi
- Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.Arteriosclerosis, thrombosis, and vascular biology · 2011 · PMID 21512161 · doi
- Human solCD39 inhibits injury-induced development of neointimal hyperplasia.Thrombosis and haemostasis · 2009 · PMID 20024507 · doi
- NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health.BioFactors (Oxford, England) · 2007 · PMID 18806312 · doi
- Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets.Blood cells, molecules & diseases · 2006 · PMID 16476557 · doi
- Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.Seminars in thrombosis and hemostasis · 2005 · PMID 15852226 · doi
- New developments in anti-platelet therapies: potential use of CD39/vascular ATP diphosphohydrolase in thrombotic disorders.Current drug targets · 2000 · PMID 11465076 · doi